title: The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism.
abstract: BACKGROUND
  Atherogenic dyslipoproteinemia is one of the most important risk factor for atherosclerotic changes development. Hypothyroidism is one of the most common causes of secondary dyslipidemias which results from reduced LDL clearance and therefore raised levels of LDL and apoB. Association between small dense LDL (sdLDL) presentation and thyroid status has been examinated using polyacrylamide gel electrophoresis for lipoprotein subfractions evaluation.
  
  
  METHODS
  40 patients with diagnosed autoimmune hypothyroidism and 30 patients with autoimmune hyperthyroidism were treated with thyroxine replacement or thyreo-suppressive treatment. In both groups lipid profiles, LDL subractions, apolipoproteins (apoA1, apoB), apoA1/apoB ratio and atherogenic index of plazma (AIP) were examined before treatment and in state of euthyreosis.
  
  
  RESULTS
  Thyroxine replacement therapy significantly reduced levels of total cholesterol (TC), LDL, triglycerides (TG) and also decreased levels of sdLDL (8,55±11,671 vs 0,83±1,693mg/dl; p<0,001), apoB and AIP. For estimation of atherogenic lipoprotein profile existence an AIP evaluation seems to be better than apoB measurement because of the more evident relationship with sdLDL (r=0,538; p<0,01). Thyreo-suppressive therapy significantly increased levels of TC, LDL, TG and apoB. The sdLDL was not found in hyperthyroid patients.
  
  
  CONCLUSIONS
  Atherogenic lipoprotein profile was present in 52.5% of hypothyroid subjects, which is higher prevalence than in normal, age-related population. Substitution treatment leads to an improvement of the lipid levels, TG, apoB, AIP and LDL subclasses. It significantly changed the presentation of sdLDL - we noticed shift to large, less atherogenic LDL particles. Significantly positive correlation between sdLDL and TAG; sdLDL and VLDL alerts to hypertriglyceridemia as a major cardiovascular risk factor.
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Minarikova
authors.forename: Ludovit
authors.initials: L
authors.lastname: Gaspar
authors.affiliation: Department of Cardiovascular Diseases, International Clinical Research Center, St, Anne's University Hospital and Masaryk University, Pekarska 53, Brno 656 91, Czech Republic. peter.kruzliak@savba.sk.
authors.forename: Peter
authors.initials: P
authors.lastname: Kruzliak
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Celecová
authors.forename: Stanislav
authors.initials: S
authors.lastname: Oravec
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D013956:Antithyroid Agents / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood* / Q000302:isolation & purification; D053299:Apolipoprotein B-100 / Q000097:blood* / Q000302:isolation & purification; D008078:Cholesterol, LDL / Q000097:blood / Q000302:isolation & purification; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D050031:Hashimoto Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy*; D008079:Lipoproteins, VLDL / Q000097:blood / Q000302:isolation & purification; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D013967:Thyroiditis, Autoimmune; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: C505693:APOA1 protein, human; C569471:APOB protein, human; D013956:Antithyroid Agents; D016632:Apolipoprotein A-I; D053299:Apolipoprotein B-100; D008078:Cholesterol, LDL; D008079:Lipoproteins, VLDL; D008713:Methimazole; D013974:Thyroxine